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Multiple sclerosis is a complex neurological dis-
ease, with 20% of risk heritability attributable to
common genetic variants, including >230 identi-
fied by genome-wide association studies. Multiple
strands of evidence suggest thatmuch of the remain-
ing heritability is also due to additive effects of com-
mon variants rather than epistasis between these
variants or mutations exclusive to individual families.
Here, we show in 68,379 cases and controls that up
to 5% of this heritability is explained by low-fre-
quency variation in gene coding sequence. We iden-
tify four novel genes driving MS risk independently
of common-variant signals, highlighting key patho-
genic roles for regulatory T cell homeostasis and
regulation, IFNg biology, and NFkB signaling. As
low-frequency variants do not show substantial link-
age disequilibrium with other variants, and as coding
variants are more interpretable and experimentally
tractable than non-coding variation, our discoveries
constitute a rich resource for dissecting the pathobi-
ology of MS.
INTRODUCTION
Multiple sclerosis (MS; MIM 126200) is an autoimmune disease
of the central nervous system and a common cause of neuro-
logic disability in young adults (Compston and Coles, 2008). It
is most prevalent in individuals of northern European ancestry
and—in line with other complex, common disorders—shows
substantial heritability (Binder et al., 2016), with a sibling stan-
dardized incidence ratio of 7:1 (Westerlind et al., 2014). Over
the last 15 years, we have identified 233 independent, com-
mon-variant associations mediating disease risk by genome-
wide association studies (GWASs) of increasing sample size
(Andlauer et al., 2016; Australia and New Zealand Multiple Scle-
rosis Genetics Consortium, 2009; Baranzini et al., 2009; Bee-
cham et al., 2013; De Jager et al., 2009; International Multiple
Sclerosis Genetics Consortium et al., 2011, 2017; Jakkula
et al., 2010; Martinelli-Boneschi et al., 2012; Nischwitz et al.,
2010; Patsopoulos et al., 2011; Sanna et al., 2010; Burton
et al., 2007). In our most recent meta-analysis of 14,802 MS
cases and 26,703 controls, these effects—including 32mapping
to classical human leukocyte antigen (HLA) alleles and other vari-Cell 175, 1679–1687, Nove
This is an open access article undation in the major histocompatibility (MHC) locus (International
Multiple Sclerosis Genetics Consortium et al., 2017; Moutsianas
et al., 2015; Patsopoulos et al., 2013)—account for 7.5% of h2g,
the heritability attributable to additive genetic effects captured
by genotyping arrays, with a total of 19.2% of h2g attributable
to all common variants in the autosomal genome (International
Multiple Sclerosis Genetics Consortium et al., 2017). MS is
thus a prototypical complex disease with a substantial portion
of heritability determined by hundreds of common genetic vari-
ants, each of which explain only a small fraction of risk (Sawcer
et al., 2014).
As with other common, complex diseaseswhere large GWASs
have been conducted, we find that although common variants
(minor allele frequency [MAF] > 5%) account for the bulk of trait
heritability, they cannot account for its entirety. Identifying the
source of this unexplained heritability has thus become a major
challenge (Manolio et al., 2009). Two hypotheses are frequently
advanced: some common variants show epistatic (i.e., non-
additive) interactions so that they contribute more risk in combi-
nation than each does alone, and a portion of risk is due to rare
variants that cannot be imputed via linkage disequilibrium to
common variants present on genotyping arrays and are there-
fore invisible to heritability calculations based on such arrays.
The only evidence we have found for epistatic interactions be-
tween common MS risk variants is between two HLA haplotype
families in the MHC locus (Moutsianas et al., 2015). This lack of
epistatic interactions is consistent with other common, complex
diseases, both of the immune system and beyond (Altshuler
et al., 2008). We have also found no evidence that mutations in
individual families drive disease risk in genome-wide linkage an-
alyses of 730 MS families with multiple affected members
(Sawcer et al., 2005). These results indicate that neither epistasis
between known risk variants normutations in a limited number of
loci are major sources of MS risk. They do not, however, pre-
clude a role for variants present in the population at low fre-
quencies, which cannot be imputed but are likely to individually
contribute moderate risk.
Here, we report our assessment of the contribution of low-
frequency variation in gene coding regions to MS risk. We con-
ducted a meta-analysis of 120,991 low-frequency coding
variants across all autosomal exons, including 104,218 non-syn-
onymous and 2,276 nonsense variants, which are more likely to
have a phenotypic effect. We analyzed a total of 32,367 MS
cases and 36,012 controls drawn from centers across Australia,
10 European countries, and multiple US states, which we geno-
typed either on the Illumina HumanExome Beadchip (exome
chip) or on a custom array (the MS chip), incorporating thember 29, 2018 ª 2018 The Author. Published by Elsevier Inc. 1679
er the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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Figure 1. Rare-Coding Variants Are Associated to Multiple Sclerosis Risk in a Multi-cohort Study
(A–C) We analyzed 120,991 low-frequency non-synonymous coding variants across all autosomal exons in 32,367 MS cases and 36,012 controls drawn across
the International Multiple Sclerosis Genetics Consortium centers. We find evidence for association with both common variants with combinedMAF > 5% (A) and
with rare variants across the autosomes (B). We sourced samples from Australia, 10 European countries, and the United States (C).
See also Figures S2 and S3.exome chip content (International Multiple Sclerosis Genetics
Consortium et al., 2017), and which satisfied our stringent quality
control filters (Figure S1 and Table S1). The exome array is a
cost-efficient alternative to exome sequencing, capturing
approximately 88% of low-frequency and rare-coding variants
present in 33,370 non-Finnish Europeans included in the Exome
Aggregation Consortium (MAFs between 0.0001 and 0.05; Fig-
ure S1), and <5% of the extremely rare alleles present at even
lower frequencies. Our studywaswell powered, with 80%power
to detect modest effects at low frequency (odds ratio [OR] = 1.151680 Cell 175, 1679–1687, November 29, 2018at MAF = 5%) and rare variants (OR = 1.5 at MAF = 0.5%) at a
significance threshold of p < 3.5 3 107 (Bonferroni correction
for the total number of variants genotyped).
RESULTS
We first assessed the contribution of individual variants to MS
risk by conducting a meta-analysis of association statistics
across 14 country-level strata (Figure 1 and Table S1). We
used linear mixed models to correct for population structure in
Table 1. Coding Variants Associated to Multiple Sclerosis Risk
Chr Position rsID Minor Allele MAF
Studies
Observed P Value OR LCI UCI Gene AA Change
14 88452945 rs11552556 A 3.9% 14 5.759E14 0.95 0.93 0.97 GALC Synonymous D84D
19 10463118 rs34536443 G 4.1% 13 6.282E13 0.95 0.93 0.97 TYK2 Missense P1104A
10 72360387 rs35947132 A 5.0% 14 1.043E10 1.04 1.02 1.06 PRF1 Missense A91V
2 179315031 rs61999302 T 5.6% 12 6.467E10 0.95 0.93 0.97 PRKRA Missense D33G
2 179315726 rs62176112 A 5.6% 12 6.633E10 0.95 0.93 0.97 PRKRA Missense P11L
19 56487619 rs61734100 C 0.2% 9 1.925E07 0.78 0.67 0.91 NLRP8 Missense I942M
12 48191247 rs148755202 T 1.4% 14 2.597E07 0.94 0.91 0.98 HDAC7 Missense R166H
We analyzed 120,991 low-frequency non-synonymous coding variants across all autosomal exons in 32,367 MS cases and 36,012 controls drawn
from centers across Australia, 10 European countries, and multiple US states. Genome positions are relative to hg19. The two variants in PRKRA
are in linkage disequilibrium (R2 = 1, D‘ = 1 in the 1000Genomes European samples). These variants lie in common variant risk loci found in our previous
GWAS (International Multiple Sclerosis Genetics Consortium et al., 2017).13 of these strata, estimated from the 16,066 common, synony-
mous coding variants present on the exome chip (i.e., variants
with MAF > 5% in our samples). We included population struc-
ture-corrected summary statistics for the remaining cohort (from
Germany), which has been previously described (Dankowski
et al., 2015). As expected, we saw a strong correlation between
effect size and variant frequency, with rarer alleles exerting larger
effects (Figure S2). We found significant association betweenMS
risk and seven low-frequency coding variants in six genes outside
the extended MHC locus on chromosome 6 (Table 1 and Fig-
ure S3). Two of these variants (TYK2 p.Pro1104Ala, overall MAF
4.1% in our samples; GALC p.Asp84Asp, overall MAF 3.9%) are
in regions identified by our latest MS GWAS and show linkage
disequilibrium with the common-variant associations we have
previously reported (International Multiple Sclerosis Genetics
Consortium et al., 2011). The remaining associations are novel,
with the variants neither in linkage disequilibrium nor physical
proximity to common variant association signals and thus not
imputable in our GWASs (Table S2).
We were struck by the observation that the minor allele is pro-
tective in six of the seven cases in Table 1, a trend we also
observe at less stringent significant thresholds (Figure S2). This
pattern is unusual in common-variant studies: for example, in
our most recent GWAS, 101/200 non-MHC effects showed
that the minor allele increases risk. To test if this phenomenon
is due to our strata containing more cases than controls, we
randomly resampled 4,000 affected and 4,000 unaffected sam-
ples in our three largest strata and calculated association statis-
tics as for our main analysis. In this symmetric design, we found
no bias toward protective minor alleles at even modest levels of
significance (Table S3). Thus, low-frequency variants do not
preferentially decrease MS risk rather than increase it.
Though we are able to identify individual low-frequency vari-
ants associated with MS risk, we recognize that we cannot
detect all such variants at genome-wide significance, even in a
study of this magnitude. We thus sought to quantify the overall
contribution of low-frequency coding variation to MS risk. We
used a restricted maximum-likelihood approach to model herita-
bility attributable to genotypic variation across the genome that
was initially developed for common-variant analyses (Yang
et al., 2011) and later shown to also performwell for rare variants,as in the present case (Mancuso et al., 2016). In each of the 13
strata that comprise our data, we estimated the proportion of
heritability explained by common (MAF > 5%) and low-frequency
(MAF% 5%; Table S4) variants on the exome arrays (Yang et al.,
2011). We included genotype-derived principal components to
further control for population stratification. By meta-analyzing
these estimates across the twelve strata where the restricted
maximum likelihood model converged, we found that low-fre-
quency variants explain 11.34% (95% confidence interval
11.33%–11.35%) of the observed difference between cases
and controls (mean estimate 4.1%on the liability scale; Figure 2).
We further partitioned the low-frequency variants into intermedi-
ate (5% > MAFR 1%) and rare (MAF < 1%) and found that the
latter alone explain 9.0% (95% confidence interval 8.9%–
9.1%) on the observed scale (mean estimate 3.2% on the liability
scale; Figure 2). We note that six of the eight genome-wide
significant variants presented in Table 1 are of intermediate
frequency and thus are not included in the rare category. We
capture the majority, though not all, of known common risk var-
iants to some extent with the common variants on the exome
chip (Table S5); our analysis therefore adequately, though imper-
fectly, models this portion of the frequency spectrum. Our results
thus indicate that many more non-synonymous rare variants
contribute to MS risk but are not individually detectable at
genome-wide thresholds, even in large studies like ours.
In this study, we show that low-frequency coding variation
explains a fraction of MS risk that cannot be attributed to com-
mon variants across the genome. We capture most, but not all,
low-frequency missense variants (Figure S1), suggesting our
heritability estimates for low-frequency and rare variation are
conservative. This broadly agrees with previous reports that
such variants contribute to complex traits, including Alzheimer’s
disease (Sims et al., 2017) and schizophrenia (Purcell et al.,
2014), where heritability modeling similar to ours supports a
role for rare variants. Studies of quantitative phenotypes shared
by the entire population, such as height (Marouli et al., 2017),
serum lipid levels (Liu et al., 2017), and blood cell traits (Chami
et al., 2016; CHARGE Consortium Hematology Working Group,
2016) have also reported novel associations to low-frequency
coding variants outside the large number of known GWAS loci
in each trait. However, a meta-analysis of different type 2Cell 175, 1679–1687, November 29, 2018 1681
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Figure 2. Rare Variants Explain a Substantial Portion of Multiple Sclerosis Heritability
We estimated the MS risk heritability explained by common variants (MAF > 5%) and low-frequency non-synonymous coding variation (MAF < 5%) in each of 13
cohorts genotyped on the exome chip using genome-wide complex trait analysis (GCTA; top). By meta-analyzing these estimates across cohorts, we found that
low-frequency variants explain 11.34% of heritability on the observed scale, which corresponds to 4.1% on the liability scale (right top). After dividing the low-
frequency variants into intermediate (5% > MAF > 1%) and rare (MAF < 1%; bottom), we found that the latter alone explains 9.0% heritability on the observed
scale (3.2% on the liability scale; bottom right). Meta-analysis confidence intervals are small and visually occluded by themean estimate plot characters. Cohorts
(abbreviations as in Table S1) are ordered by sample size, with the percentage of the overall sample size shown in each subplot title. We could not obtain es-
timates for either model for our Finnish cohort (see STARMethods; not shown), or for the three-component model for our Belgian cohort (bottom, top row, fourth
from left). Both cohorts are small, which may explain the failure to converge.diabetes study designs found no associations outside common-
variant GWAS regions (Fuchsberger et al., 2016), though this
may be due to the heterogeneity of sample ascertainment and
study design. In aggregate, therefore, our results and these
past studies demonstrate that rare coding variants contribute a
fraction of common, complex trait heritability. These results
also agree with both theoretical expectation and empirical ob-
servations that low-frequency coding variants are under natural
selection and are unlikely to increase in frequency in the popula-
tion (Nelson et al., 2012; Schoech et al., 2017; Zeng et al., 2018).
Thus, some portion of disease-associated variants, and hence
the genes they influence, may not be detectable with conven-
tional GWAS designs.
The newly discovered genes have clear immunological func-
tions, confirming that MS pathogenesis is primarily driven by
immune dysfunction. The associated polymorphisms show
negligible linkage disequilibrium with other variants (Table S2),1682 Cell 175, 1679–1687, November 29, 2018so the genes harboring them are likely to be relevant to disease.
PRF1 encodes perforin, a key component of the granzyme-
mediated cytotoxicity pathways used by several lymphocyte
populations. In addition to cytotoxic lymphocytes and natural
killer (NK) cells (House et al., 2015), perforin-dependent cytotox-
icity is also seen in CD4+FOXP3+ regulatory T cells (Tregs), which
show aberrant, T helper-like IFNg secretion inMSpatients (Dom-
inguez-Villar et al., 2011). The MS risk variant rs35947132
(p.Ala91Val) is associated with a decrease in target cell-killing ef-
ficiency and increases in IFNg secretion byNK cells (House et al.,
2015), which aligns with the aberrant Treg phenotype observed
in MS. This decreased cytotoxicity efficiency will prolong
average cell-cell interactions with target cells, and such
extended interactions are known to increase T cell-receptor-
mediated signaling and induce changes to T cell phenotypes,
especially secretion of IFNg and other cytokines (Constant
et al., 1995). Similarly, HDAC7 encodes the class II histone
deacetylase 7, which potentiates the repressive effects of
FOXP3, the master regulator governing naive CD4+ T cell devel-
opment into Tregs (Bettini et al., 2012; Li et al., 2007). It also reg-
ulates T cell survival during their development in the thymus
(Kasler et al., 2011). PRKRA encodes protein kinase interferon-
inducible double-stranded RNA-dependent activator; in
response to double-stranded RNA due to virus infection, it
heterodimerizes with protein kinaseR to inhibit EIF2a-dependent
translation, resulting in upregulation of nuclear factor kB (NFkB)
signaling, interferon production, and eventually, apoptosis
(Sadler and Williams, 2008). NFkB-mediated signaling is a core
feature of MS pathogenesis, which we have shown to be altered
by at least one MS-associated variant (Housley et al., 2015) and
may be the relevant mechanism for this gene. Finally, NLRP8 is
an intracellular cytosolic receptor active in innate immune re-
sponses; the Ile942Met MS risk variant rs61734100 is detected
only in individuals with European ancestry in ExAC, consistent
with the higher prevalence of MS in European ancestry
populations.
DISCUSSION
Broadly, therefore, our results show that low-frequency genetic
variation explains a portion of MS risk and that this variation im-
pacts genes not detectable by common-variant association
studies. Our heritability modeling demonstrates that more low-
frequency and rare-variant associations remain to be discov-
ered, though larger sample sizes will be required to increase
statistical power. Recent attention has focused on changes to
the adaptive immune system as pathogenic for MS, particularly
to functional changes in helper T cell subsets and B cells after
they have been released from the thymus and bone marrow,
respectively, into the peripheral blood stream. These processes
remain important to pathogenesis and are supported by a wealth
of data, including our own GWAS (International Multiple Scle-
rosis Genetics Consortium et al., 2017). However, two of the
four new genes we report (PRKRA and NLRP8) have clear func-
tions in innate immunity, and HDAC7 plays a central role in the
development of T cells in the thymus. Roles for both innate im-
mune function and thymic development in MS pathogenesis
are also supported by pathway analyses of our most recent
GWAS data (International Multiple Sclerosis Genetics Con-
sortium et al., 2017), an independent observation due to the
lack of linkage disequilibrium (LD) between the variants in this
study and those in our GWAS and the non-overlapping sample
collections. Our data thus expand the scope of immune function
relevant to MS pathogenesis.
The mechanisms whereby our newly discovered variants
alter MS risk will require detailed experimental dissection:
even when we can directly implicate specific genes and vari-
ants, these can have diverse consequences across multiple
cell types. For example, perforin 1 has key—and potentially
distinct—roles in cytotoxic T cells, regulatory helper T cells,
NK cells, and other cell types. Both the effects of the variant
on each of these functions and their relevance to MS pathogen-
esis will thus require demonstration, as is the case for the
genes central to IFNg biology, Treg function, and the NFkB
signaling pathway.STAR+METHODS
Detailed methods are provided in the online version of this paper
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EXPERIMENTAL MODEL AND SUBJECT DETAILS
We assembled a total of 76,140 samples (36,219 cases, 38,629 controls and 1,292 samples with missing phenotype information)
from across the International MS Genetics Consortium (IMSGC; Table S1). All individuals gave informed consent at enrolment,
and recruitment wasmonitored by research ethics boards inAustralia: University of Tasmania; BondUniversity; University of Sydney.
Belgium: Katholieke Universiteit, Leuven.Canada: McGill University, Montreal. Denmark: University of Copenhagen. Finland: Univer-
sity of Helsinki. France: Hoˆpital Pitie´-Salpeˆtrie`re, Paris; Hoˆpital Neurologique Pierre Wertheimer, Bron; Universite´ de Nantes.
Germany: University of Lu¨beck; Max Planck Institute of Psychiatry, Munich; Technische Universita¨t Mu¨nchen; Johannes Gutenberg
University-Medical Center, Mainz; Klinikums at Augsburg, Hanover and Großhadern Munich; Universita¨tsklinikums of Hamburg,
Erlangen, Gießen/Marburg, Leipzig, Ko¨ln, Mu¨nster, Heidelberg, Rostock, and Tu¨bingen, the Universita¨t Ulm. Greece: University of
Larissa. Italy: University of Eastern Piedmont, Novara; Ospedale Maggiore, Novara; San Raffaele Scientific Institute, Milan; University
of Milan.Netherlands: ErasmusMC, Rotterdam; VUUniversity Medical Center, Amsterdam.Norway: University of Bergen; University
of Oslo. Spain: Universitat Auto`noma de Barcelona. Sweden: Karolinska Institutet, Stockholm. Switzerland: University Hospital Zur-
ich. United States of America: Yale University, New Haven CT; Brigham & Women’s Hospital, Boston MA; the University of Miami,
Miami FL; UCSF and USB San Francisco, CA; Kaiser Permanente Divison of Research, Oakland, CA; Johns Hopkins University Bal-
timore MD; Washington University St Louis, St Louis MO; Vanderbilt University Medical Center, Nashville TN; Brigham Young Uni-
versity, Provo, UT; Case Western Reserve University, Cleveland, OH; The University of Pennsylvania and the Children’s Hospital of
Philadelphia, PA; Columbia University Medical Center, New York, NY. United Kingdom: MRC Biostatistics Unit, Cambridge; Univer-
sity of Cambridge; Keele University; King’s College London; University of Oxford; and University College London.
METHOD DETAILS
We genotyped these either on the Illumina HumanExome Beadchip (exome chip) or on a previously described custom array (Inter-
national Multiple Sclerosis Genetics Consortium et al., 2017) including the exome chip content, both manufactured by Illumina Inc.
We called genotypes both with Illumina’s default algorithm, gencall, and zCall, specifically developed to call low-frequency variants
where all three groups of genotypes may not be observed (Goldstein et al., 2012).
An overview of our quality control process is shown in Figure S1; we used PLINK (Purcell et al., 2007) for all analyses unless other-
wise noted. Briefly, we first excluded samples with low genotyping rate, extreme heterozygosity rate, inconsistent genotypic and re-
corded sex; we also removed closely related samples, keeping the relative with least missing data. Next, we removed population
outliers by calculating genotype principal components using 16,066 common variants in linkage disequilibrium (r2 < 0.1) across
the exome. We used EIGENSOFT 6 (Price et al., 2006) and FlashPCA (Abraham and Inouye, 2014) for cohorts with more
than 10.000 individuals. We next removed variants with > 3% gencall missing data rate for variants with minor allele frequencye1 Cell 175, 1679–1687.e1–e2, November 29, 2018
MAF > 5%, or > 1% zCall missing data rate for variants with MAF < 5%.We also removed variants out of Hardy-Weinberg equilibrium
(p < 105). Next, we removed samples with high similarity in missing genotypes (‘‘identity by missingness’’) indicative of production
artifact, and samples with missing phenotype information. Finally, we again removed any remaining population outliers using projec-
tion principal component analysis. We calculated 30 principal components for 1,092 individuals in 1000 Genomes reference popu-
lations, again using the 16,066 common variants in linkage disequilibrium (r2 < 0.1) across the exome. We then projected the IMSGC
samples into this space and excluded individuals more than six standard deviations from loading means as previously described
(Price et al., 2006). We performed the projection and outlier detection and removal steps a total ten times to gradually remove
more subtle population outliers.
We compiled cases and controls into strata for analysis as shown in Table S1. In total, we removed 17,938/76,140 (24%) samples
either due to lowdataquality or aspopulationoutliers, leaving afinal dataset of 27,891casesand30,298controls in 13 strata (FigureS1
and Table S1). Separately, we included summary statistics from 4,476MS cases and 5,714 controls fromGermany, genotyped on the
exome chip as previously described (Dankowski et al., 2015), giving us a total of 32,367 MS cases and 36,012 controls for analysis.
QUANTIFICATION AND STATISTICAL ANALYSIS
Exome chip coverage of ExAC variants
To assess how thoroughly the exome chip assesses low-frequency coding variation genome-wide, we compared it to the list of var-
iants reported by the Exome Aggregation Consortium, ExAC (Lek et al., 2016), in their data release version 1. We filtered their sum-
mary table of all ExAC variants (available at ftp://ftp.broadinstitute.org/pub/ExAC_release/release1/manuscript_data/ExAC.r1.sites.
vep.table.gz and last accessed 15November 2017) for nonsynonymous coding variants passing their quality control, with at least one
minor allele observed in non-Finnish European samples. We identified which of these variants are represented on the exome chip by
comparing genomic coordinates.
Univariate association analysis
We used mixed linear models for association analysis, as implemented in GCTA (Yang et al., 2011). In each of our 13 genotype-level
strata, we calculated genetic relatedness matrices from 16,066 common, noncoding variants (overall MAF > 0.05) in linkage equilib-
rium (all pairwise r2 < 0.1) present on the exome chip, and with these calculated univariate association statistics for each autosomal
variant present on the exome chip. To further control for population stratification, we also calculated genotypic principal components
with the 16,066 common variants, and included these as covariates to the association analysis. We also included genotypic sex and
chip type as covariates. We combined statistics across strata using inverse-variance-weighted meta-analysis, also as implemented
in GCTA (Yang et al., 2011). As the bulk of exome chip variants are not common and do not show appreciable linkage disequilibrium,
we controlled for multiple tests with a Bonferroni correction for the number of low-frequency variants, to give a genome-wide signif-
icance threshold of p < 3.583 10e-7 (0.05/139,764 variants with a combined MAF < 0.05 in controls and a heterogeneity index I2 < 50
in our meta-analysis).
Heritability estimation
WeusedGCTA to calculate the heritability attributable to groups of variants in each of our 13 genotype-level strata (Yang et al., 2011).
In each stratum, we ran two sets of models: a two-component model, estimating the heritability attributable to common and low-fre-
quency (MAF% 0.05) variants; and a three component model with rare (MAF% 0.01), intermediate (0.01 < MAF% 0.05), and com-
mon variants. In all strata, common variants are the set of 16,066 independent variants (overall MAF > 0.05) used for population
stratification calculations in the univariate analysis above. We computed genetic relatedness matrices for each component of
each model, then calculated narrow-sense heritability (h2) with 100 iterations of constrained restricted maximum likelihood
(REML) fitting, assuming a disease prevalence of 0.001. We also included the principal components of population structure
computed for the univariate analysis as covariates. As anticipated, several of the smaller cohorts presented fitting issues: no models
converged for FIN; both three-component and two-component fits for UCSF2, and the three-component model for GRE would not
converge under constraint and so were run without constraints; and the three-component model for BEL converged on two exactly
equally likely solutions after 10,000 iterations. For the latter, we chose the most conservative estimates of variance explained. We
combined these estimates with inverse variance-weighted meta-analysis.
DATA AND SOFTWARE AVAILABILITY
Meta-analysis summary statistics are available at http://imsgc.net/. Due to varying privacy laws across countries, some of our ge-
notype data are available from the European Genome-phenome Archive (deposited under accession EGAS00001003195), with
the remainder available directly from participating centers. A single request for all data access may be submitted to the IMSGC
Data Access Committee (dac@imsgc.net). Our QC and analysis pipeline is available at https://github.com/cotsapaslab/
IMSGCexomechip.Cell 175, 1679–1687.e1–e2, November 29, 2018 e2
Supplemental Figures
(legend on next page)
Figure S1. Data Quality Overview, Related to STAR Methods
(A) QC process. We assembled 42 cohorts of data (either entire country-level collections or groups of samples processed as a batch; Table S1). We called
common variant genotypeswith the standard algorithm provided by Illumina (GenCall), and low-frequency variants with zCall, an algorithm specifically developed
to call these variants on the exome chip (Goldstein et al., 2012). We performed initial quality control on each cohort separately to account for variation between
batches and cohorts (upper gray region), then merged cohorts into 13 country-level strata. To ensure that these strata were uniform we then performed stringent
quality control on each stratum (lower gray region) to produce our final dataset.
(B) the exome chip captures a large fraction of ExAC (release version 1) low-frequency miss-sense variants. The exome chip captures the majority of variants
present in ExAC (Lek et al., 2016) down to aminor allele frequency0.0005, belowwhich a large number of variants is observed (left). Thus, the overall coverage at
very rare alleles (5 3 104 > MAF > 1.5 3 105, corresponding to a single allele seen in 33,370 non-Finnish European individuals in ExAC) is low (right).
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Figure S2. Low-Frequency Variant Association Statistic Characteristics, Related to Figure 1
(A) effect sizes increase at low minor allele frequency. We conducted a meta-analysis of 120,991 low-frequency coding variants across all autosomal exons,
concentrating on non-synonymous variants which are more likely to have a phenotypic effect. We analyzed a total of 32,367 MS cases and 36,012 controls in
thirteen strata. Here, we show that estimates of effect size (b or log odds ratio, y axis) increase at low allele frequency (number of minor alleles present in control
samples, x axis). Becausemany low-frequency variants are not present in all cohorts, we stratify these data by number of cohorts in which a variant is polymorphic
(subplots). Rarer variants have larger estimated effect sizes and are present in fewer cohorts.
(B) forest plots for genome-wide significant low-frequency variants. Seven variants in six genes are significant in our analysis (p < 3.5 3 107, Bonferroni
correction for the total number of variants genotyped). Two of these (TYK2 p.Pro1104Ala andGALC p.Asp84Asp), are in linkage disequilibriumwith knownGWAS
hits. Studies are ordered by increasing sample size.
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Figure S3. Patterns of Association for Common and Rare Variants in Seven Genome-wide Significant Loci, Related to Figure 1
Plots are centered on the seven variants reported in Figure 1 and Table 1. Each show LD and association signal of low frequency variants (circles, this study), and
common variants from our most recent GWAS (squares, 14,802MS cases and 26,703 controls; International Multiple Sclerosis Genetics Consortium et al., 2017)
and the ImmunoChip meta-analysis (diamonds; Beecham et al., 2013). For GALC and TYK2, our most associated variants, rs11552556 and rs34536443
respectively, capture the common variant signals we have previously reported (panels A and G). For the remaining loci, our most associated variants show no LD
to other variants, with no evidence of association in our common variant studies (panels B-F).
